1) The FAST-MI network in France characterized over 3,600 acute myocardial infarction patients between 2005-2010, collecting DNA samples, serum, and over 400 clinical variables to study the pathophysiology and pharmacogenetics of cardiovascular disease. 2) Analysis of the FAST-MI data identified genetic variants that influence drug absorption and metabolism, and found associations between serum levels of secretory phospholipase A2, its genetic variants, and cardiovascular outcomes after one year. 3) The FAST-MI network continues ongoing studies, has published numerous papers, and aims to further understanding of biomarkers and genetic influences on diabetes and cardiovascular drug response.